Filing Overview
The source document is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2016, filed August 9, 2016. The request identifies Spyre Therapeutics, Inc.; the supplied filing does not use that name, so the registrant identity should be verified.
Business Context and Reporting Period
Aeglea was an early-stage biotechnology company developing enzyme-based therapeutics targeting amino-acid metabolism for inborn errors of metabolism and cancer. Its lead candidate was AEB1102, being developed for Arginase I deficiency, advanced solid tumors, and hematological malignancies. The company had no product revenue and relied primarily on equity financing and a CPRIT research grant.
During the quarter, Aeglea initiated a Phase 1 study of AEB1102 for Arginase I deficiency. After quarter-end, it initiated a Phase 1 study in relapsed/refractory AML and MDS and received European Orphan Drug Designation for AEB1102 in Arginase I deficiency.
Key Financial Metrics
| Metric | Three months ended June 30, 2016 | Three months ended June 30, 2015 | Six months ended June 30, 2016 | Six months ended June 30, 2015 |
|---|---|---|---|---|
| Grant revenue | $1.4 million | $3.4 million | $2.2 million | $3.4 million |
| Research and development expense | $4.4 million | $2.7 million | $8.0 million | $4.4 million |
| General and administrative expense | $2.4 million | $2.1 million | $4.3 million | $3.0 million |
| Total operating expenses | $6.9 million | $4.9 million | $12.3 million | $7.3 million |
| Net loss | $5.4 million | $1.4 million | $10.0 million | $3.9 million |
| Net loss per share | $0.46 | $2.44 | $1.61 | $7.12 |
| Net cash used in operating activities | Not separately provided | Not separately provided | $8.6 million | $6.3 million |
At June 30, 2016, cash and cash equivalents were $70.6 million, marketable securities were $2.9 million, and total liquidity including those assets was $73.6 million. Working capital was $73.5 million, accumulated deficit was $33.6 million, and total liabilities were $3.4 million. Management reported no debt or debt facility.
Cash increased by $41.3 million during the first six months, primarily because of $49.3 million of net IPO proceeds, partially offset by $8.6 million of operating cash use. The company completed its IPO in April 2016, selling 5.5 million shares for gross proceeds of $54.8 million and net proceeds of $47.3 million.
Material Changes Versus Prior Comparable Period
- Quarterly grant revenue decreased 60% and six-month grant revenue decreased 35%, primarily because the 2015 period included recognition of accumulated qualifying expenditures upon execution of the CPRIT grant agreement.
- Quarterly research and development expense increased 62%; six-month expense increased 84%, reflecting higher nonclinical, clinical, and personnel costs associated with AEB1102 development.
- Quarterly general and administrative expense increased 15%; six-month expense increased 44%, largely due to increased personnel, professional services, insurance, and public-company costs.
- Quarterly net loss increased to $5.4 million from $1.4 million; six-month net loss increased to $10.0 million from $3.9 million.
- The company completed its IPO and converted all outstanding preferred stock into common stock. Common shares outstanding increased to 13.4 million at June 30, 2016 from 757,336 at December 31, 2015.
- Stock-based compensation increased to $529,000 for the six months from $184,000 in the prior-year period.
Guidance, Outlook, Risks, and Unusual Items
Management expected substantial operating losses to continue as clinical development and other research activities expanded. It stated that existing cash, cash equivalents, and marketable securities were expected to fund operations through at least March 31, 2018, although the estimate depended on assumptions that could prove incorrect. Additional financing would be required to complete all planned development activities.
The company had collected $6.7 million of the CPRIT grant proceeds through June 30, 2016, with $13.1 million available for future collection and a $1.6 million grant receivable outstanding. The grant carries potential low- to mid-single-digit royalties on future applicable revenues, declining to less than 1% after repayment of a specified multiple of grant funding.
Key risks included clinical-trial failure or delays, patient-enrollment constraints in rare diseases, regulatory approval uncertainty, adverse events, dependence on third-party manufacturers and contract research organizations, need for additional capital, intellectual-property challenges, competition, reimbursement uncertainty, and inability to commercialize product candidates. The filing disclosed serious adverse events, including deaths, in an oncology Phase 1 study, although management stated that none was assessed as related to AEB1102.
The company reported effective disclosure controls at June 30, 2016 and no material changes to internal control over financial reporting during the period. It reported no material pending legal proceedings and no off-balance-sheet arrangements. Related-party consulting payments to the CEO’s spouse totaled $324,000 for the six months ended June 30, 2016.
Important Facts for Investors to Verify
- Confirm whether this Aeglea filing is the intended document for Spyre Therapeutics, Inc.
- Verify the timing, enrollment, safety findings, and topline-data plans for all AEB1102 Phase 1 trials.
- Assess the cash runway against actual quarterly cash burn and anticipated clinical, manufacturing, and public-company costs.
- Review the terms, remaining availability, reimbursement conditions, and potential royalty obligations under the CPRIT grant.
- Evaluate future dilution risk from equity financing, stock options, restricted shares, and shares becoming eligible for resale after the IPO lock-up period.
- Review the company’s dependence on third-party manufacturing, the University of Texas at Austin, CROs, and licensed intellectual property.
- Confirm that no material adverse events, regulatory holds, litigation, or internal-control deficiencies arose after the filing date.